Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still’s disease

References

• Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006;65(5):564–72.
   PubMed Web of Science ®Google Scholar
• Masson C, Le Loet X, Liote F, Dubost JJ, Boissier MC, Perroux-Goumy L, et al. Comparative study of 6 types of criteria in adult Still's disease. J Rheumatol. 1996;23(3):495–7.
   Google Scholar
• Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81(3):194–200.
   Google Scholar
• van de Putte LB, Wouters JM. Adult-onset Still's disease. Bail-fieres Clin Rheumatol. 1991;5(2):263–75.
   PubMed Web of Science ®Google Scholar
• Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ. Adult onset Still's disease and viral infections. Ann Rheum Dis. 1988;47(9):764–7.
   PubMed Web of Science ®Google Scholar
• Escudero FJ, Len 6, Falco V, de Sevilla TF, Sellas A. Rubella infection in adult onset Still's disease. Ann Rheum Dis. 2000;59:493.
   PubMedGoogle Scholar
• Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, et al. Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol. 1990;17(8):1058–63.
   PubMed Web of Science ®Google Scholar
• Perez C, Artola V. Adult Still's disease associated with Myco-plasma pneumoniae infection. Clin Infect Dis. 2001;32:E105–6.
   PubMed Web of Science ®Google Scholar
• Kadar J, Petrovicz E. Adult-onset Still's disease. Best Pract Res Clin Rheumatol. 2004;18:663–76.
   PubMed Web of Science ®Google Scholar
• Chen D, Lan J, Lin F, Hsieh T, Wen M. Predominance of Thl cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis. 2004;63(10):1300–6.
   Google Scholar
• Caramaschi P, Biasi D, Carletto A, Bambara LM. A case of adult onset Still's disease treated with infliximab. Clin Exp Rheumatol. 2002;20(1):113.
   PubMed Web of Science ®Google Scholar
• Dilhuydy MS, Vatan R, Etienne G, Longy-Boursier M, Mercié P. Prolonged efficacy of infliximab for refractory adult-onset Still's disease. Clin Exp Rheumatol. 2005;23(1):121–2.
   Google Scholar
• Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor a blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–6.
   PubMed Web of Science ®Google Scholar
• Godinho F, Santos M, da Silva JC. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis. 2005;64(4):647–8.
   PubMedGoogle Scholar
• Fitzgerald AA, LeClercq SA, Yan A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794–803.
   Google Scholar
• Iwamoto M. Macrophage activation syndrome associated with adult-onset Still's disease. Nihon Rinsho Meneki Gakkai Kaishi. 2007 ;30(6) : 428–31.
   PubMedGoogle Scholar
• Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still's disease: manifesta-tions, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118–36.
   Google Scholar
• Fautrel B, Borget C, Rozenberg S, Meyer O, Le Loa X, Masson C, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol. 1999;26(2):373–8.
   PubMed Web of Science ®Google Scholar
• Mahmud T, Hughes GR. Intravenous immunoglobulin in the treatment of refractory adult Still's disease. J Rheumatol. 1999;26:2067–8.
   PubMed Web of Science ®Google Scholar
• Vignes S, Wechsler B, Amoura Z, Papo T, Frances C, Le 'Thi Huong D, et al. Intravenous immunoglobufin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16:295–8.
   Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refrac-tory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009;19(1):69–72.
   Google Scholar
• Murakami K, Fujii T, Yukawa N, Yoshifuji H, Kawabata D, Tanaka M, et al. Successful treatment of a patient with refractory adult Still's disease by Tacrolimus. Mod Rheumatol. 2007 ; 17(2): 167–70.
   PubMedGoogle Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Coch-rane database of systematic reviews, 2009. Issue 1, art. no.: CD005121. doi:10.1002/14651858.CD005121.pub3.
   Google Scholar
• Kalfiolias George D, Georgiou Panagiotis E, Antonopoulos Ioannis A, Andonopoulos Andrew P, Stamatis-Nick C Liossis. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842–3.
   Google Scholar
• Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67(3):302–8,
   PubMed Web of Science ®Google Scholar
• Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y, et al. Elevated serum interleukin-6, interferon-gamma, and tumor necrosis factor alpha levels in patients with adult Still's disease. J Rheumatol. 1998;25(2):396–8.
   PubMed Web of Science ®Google Scholar